102 related articles for article (PubMed ID: 954793)
1. Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer.
Mangioni C; Bolis G; Natale N; Morasca L
Eur J Cancer (1965); 1976 May; 12(5):353-6. PubMed ID: 954793
[No Abstract] [Full Text] [Related]
2. Treatment of 126 cases of advanced ovarian carcinoma with cyclophosphamide.
Beck RE; Boyes DA
Can Med Assoc J; 1968 Mar; 98(11):539-41. PubMed ID: 5647240
[No Abstract] [Full Text] [Related]
3. [Therapeutic trial of a combination of cytostatic agents in advanced ovarian carcinoma].
Brandl K
Zentralbl Gynakol; 1970 Feb; 92(8):233-9. PubMed ID: 5505972
[No Abstract] [Full Text] [Related]
4. Triple massive-dose drug therapy in combined treatment of advanced ovarian carcinoma.
Vahrson H
Geburtshilfe Frauenheilkd; 1973 Apr; 33(4):293-6. PubMed ID: 4196905
[No Abstract] [Full Text] [Related]
5. [On quantitative changes in the leukocytes and thrombocytes after chemotherapy in patients with malignant tumors of the ovaries].
Livshits MA
Vopr Onkol; 1966; 12(8):42-6. PubMed ID: 4972210
[No Abstract] [Full Text] [Related]
6. Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
Andersson H; Friberg LG; Horvath G; Johansson O; Akesson M; Westberg R
Acta Oncol; 1995; 34(6):821-7. PubMed ID: 7576751
[TBL] [Abstract][Full Text] [Related]
7. Intermittent high-dose cyclophosphamide (NSC-26271) treatment of stage III ovarian carcinoma.
Buckner CD; Briggs R; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Storb R; Thomas ED
Cancer Chemother Rep; 1974; 58(5 Pt 1):697-703. PubMed ID: 4426048
[No Abstract] [Full Text] [Related]
8. Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum.
Sessa C; D'Incalci M; Colombo N; Pecorelli G; Mangioni C
Cancer Chemother Pharmacol; 1983; 11(1):33-4. PubMed ID: 6683998
[TBL] [Abstract][Full Text] [Related]
9. [Use of large single doses of cyclophosphane (endoxan)].
Garin AM
Vopr Onkol; 1970; 16(11):43-8. PubMed ID: 4929048
[No Abstract] [Full Text] [Related]
10. Cyclophosphamide-induced immune thrombocytopenia in a patient with ovarian carcinoma successfully treated with intravenous gamma globulin.
Mueller-Eckhardt C; Küenzlen E; Kiefel V; Vahrson H; Graubner M
Blut; 1983 Mar; 46(3):165-9. PubMed ID: 6186321
[No Abstract] [Full Text] [Related]
11. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208).
Kyle RA; Seligman BR; Wallace HJ; Silver RT; Glidewell O; Holland JF
Cancer Chemother Rep; 1975; 59(3):557-62. PubMed ID: 1203882
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate (NSC-740) with citrovorum factor (NSC-3590) rescue, alone and in combination with cyclophosphamide (NSC-26271), in ovarian cancer.
Barlow JJ; Piver MS
Cancer Treat Rep; 1976 May; 60(5):527-33. PubMed ID: 1086714
[TBL] [Abstract][Full Text] [Related]
13. 5-FU infusion and cyclophosphamide in the treatment of advanced ovarian cancer.
Izbicki RM; Baker LH; Samson MK; McDonald B; Vaitkevicius VK
Cancer Treat Rep; 1977 Nov; 61(8):1573-5. PubMed ID: 922760
[No Abstract] [Full Text] [Related]
14. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study.
Lancet; 1998 Nov; 352(9140):1571-6. PubMed ID: 9843101
[TBL] [Abstract][Full Text] [Related]
15. High-dose cyclophosphamide (NSC-26271) for recurrent or progressive ovarian adenocarcinoma.
Piver MS; Barlow JJ; Chung WS
Cancer Chemother Rep; 1975; 59(6):1157-8. PubMed ID: 769956
[No Abstract] [Full Text] [Related]
16. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.
Reyno LM; Egorin MJ; Canetta RM; Jodrell DI; Swenerton KD; Pater JL; Burroughs JN; Novak MJ; Sridhara R
J Clin Oncol; 1993 Jun; 11(6):1156-64. PubMed ID: 8501502
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide therapy in patients with advancing breast cancer following adrenalectomy and 5-fluorouracil.
Piro AJ; Wilson RE; Nevinny HB
Cancer; 1971 Jun; 27(6):1342-5. PubMed ID: 5088210
[No Abstract] [Full Text] [Related]
18. The treatment of advanced ovarian carcinoma with high dose, intravenous cyclophosphamide.
Geisler HE; Minor JR; Eastlund ME
Gynecol Oncol; 1976 Mar; 4(1):43-52. PubMed ID: 992477
[No Abstract] [Full Text] [Related]
19. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy.
van der Burg ME; Hoff AM; van Lent M; Rodenburg CJ; van Putten WL; Stoter G
Eur J Cancer; 1991; 27(3):248-50. PubMed ID: 1827305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
